{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:16:04Z","timestamp":1773011764944,"version":"3.50.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Because of high relapse rates with rituximab combinations, there is an unmet need for new therapeutic agents for treatment of indolent B-cell non-Hodgkin lymphoma (iNHL) or follicular lymphoma (FL). In previous trials, ofatumumab in combination with chemotherapy showed good results in relapsed\/refractory FL pretreated with rituximab. This phase 3 trial evaluated the efficacy and safety of single-agent ofatumumab vs single-agent rituximab in rituximab-sensitive relapsed FL that relapsed at least 6 months after completing the last prior treatment with single-agent rituximab or a rituximab-containing regimen. Patients were randomized 1:1 to receive either ofatumumab (1000 mg) or rituximab (375 mg\/m2) every week for 4 weeks for the induction phase, followed by once every 2 months for 4 additional doses. The primary endpoint, progression-free survival (PFS) and secondary endpoints, overall response rate (ORR) and overall survival (OS), were evaluated. Overall, 438 patients were assigned to receive ofatumumab (n = 219) and rituximab (n = 219). Baseline characteristics were similar in both arms. The independent review committee assessed whether median PFS was shorter in the ofatumumab arm than in the rituximab arm (16.33 vs 21.29 months), with no significant difference (hazard ratio, 1.15; 95% confidence interval, 0.89-1.49; P = .29) and also showed a lower ORR (50%) compared with the rituximab arm (66%). At the time of analysis, data were not matured for OS results. The number of grade &amp;gt;3 adverse events was higher in the ofatumumab arm (37%) than the rituximab arm (28%). Ofatumumab showed no superiority over rituximab in patients with FL who had relapsed after a rituximab-containing therapy. This study was registered at www.clinicaltrials.gov as #NCT01200589.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001942","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T17:59:54Z","timestamp":1597773594000},"page":"3886-3893","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy"],"prefix":"10.1182","volume":"4","author":[{"given":"David G.","family":"Maloney","sequence":"first","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Kasugai Municipal Hospital, Aichi, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2682-2179","authenticated-orcid":false,"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Tohoku University Hospital, Miyagi, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaclyn","family":"Davis","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Lasher","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiya","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"issue":"2","key":"2020082410344647700_B1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2020082410344647700_B2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"4","key":"2020082410344647700_B3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjh.12562","article-title":"Incidence of haematological malignancies by ethnic group in England, 2001-7","volume":"163","author":"Shirley","year":"2013","journal-title":"Br J Haematol"},{"issue":"11","key":"2020082410344647700_B4","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"issue":"1","key":"2020082410344647700_B5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1746-1596-6-33","article-title":"The predictive significance of CD20 expression in B-cell lymphomas","volume":"6","author":"Prevodnik","year":"2011","journal-title":"Diagn Pathol"},{"issue":"8","key":"2020082410344647700_B6","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020082410344647700_B7","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","article-title":"Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma","volume":"98","author":"Bachy","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"2020082410344647700_B8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00277-002-0581-1","article-title":"Randomized phase III study for the treatment of advanced indolent non-Hodgkin\u2019s lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab","volume":"82","author":"Herold","year":"2003","journal-title":"Ann Hematol"},{"issue":"12","key":"2020082410344647700_B9","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"28","key":"2020082410344647700_B10","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"2020082410344647700_B11","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/jco.2015.33.15_suppl.8503","article-title":"Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed\/refractory (RR) follicular lymphoma (FL): durable responses at lower dose level","volume":"33","author":"Advani","year":"2015","journal-title":"J Clin Oncol"},{"issue":"21","key":"2020082410344647700_B12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood.V124.21.800.800","article-title":"Ibrutinib monotherapy in relapsed\/refractory follicular lymphoma (FL): preliminary results of a Phase 2 Consortium (P2C) Trial","volume":"124","author":"Bartlett","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2020082410344647700_B13","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V124.21.802.802","article-title":"A Phase 1 evaluation of duvelisib (IPI-145), a PI3K-delta,gamma inhibitor, in patients with relapsed\/refractory iNHL","volume":"124","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2020082410344647700_B14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood.V126.23.254.254","article-title":"A phase 1 study of venetoclax (ABT-199\/GDC-0199) monotherapy in patients with relapsed\/refractory non-Hodgkin lymphoma [abstract]","volume":"126","author":"Gerecitano","year":"2015","journal-title":"Blood"},{"issue":"31","key":"2020082410344647700_B15","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"30","key":"2020082410344647700_B16","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS Study","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020082410344647700_B17","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020082410344647700_B18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2007.06916.x","article-title":"Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody","volume":"140","author":"Bleeker","year":"2008","journal-title":"Br J Haematol"},{"issue":"11","key":"2020082410344647700_B19","first-page":"103","article-title":"Novel fully human CD20 antibodies with different mechanisms of action","volume":"102","author":"Dechant","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2020082410344647700_B20","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2020082410344647700_B21","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"issue":"12","key":"2020082410344647700_B22","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2020082410344647700_B23","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2020082410344647700_B24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"13","key":"2020082410344647700_B25","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(15)00143-6","article-title":"Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study","volume":"16","author":"van Oers","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/16\/3886\/1756157\/advancesadv2020001942.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/16\/3886\/1756157\/advancesadv2020001942.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T14:35:04Z","timestamp":1598279704000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/16\/3886\/463298\/A-phase-3-randomized-study-HOMER-of-ofatumumab-vs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":25,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001942","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,18]]}}}